
Mon Medical Center achieves state first in new AFib procedure
May 25—dbeard @dominionpost.com Vandalia Health Mon Medical Center recently achieved another first-in-state in heart care by combining two technologies to treat atrial fibrillation — AFib.
Mon Health Heart & Vascular Center electrophysiologist Dr. Salam Sbaity and his team combined the application of the Watchman and the Farapulse Pulsed Field Ablation system — both from Boston Scientific — in a single procedure.
AFIb is when the top two chambers of the heart — the atria — beat too fast and with an irregular rhythm (fibrillation), Boston Scientific said.
Sbaity explained why combining the two technologies is significant. AFib is the most common abnormal heart rhythm and West Virginia is among the top three states for prevalence.
AFib symptoms include palpitations, dizziness and shortness of breath, he said, and can lead to heart failure, blood clots and stroke.
There are two main advanced treatments. One is to treat the source of clots and stroke by closing the left atrial appendage, which extends off of the left atrium. The Watchman device is used to close it off.
The other is to treat the rhythm itself, he said. Muscle sleeves lead from the atrium into four pulmonary veins and are the source of electrical instability that can start the abnormal rhythm.
The abnormal rhythm is treated via cauterization, also known as ablation. The two forms of ablation used are extreme heat — radio frequency ablation — and extreme cold, cryoablation.
Boston Scientific announced in January 2024 that the FDA approved a new form, pulsed field ablation, with the Farapulse. The Farapulse catheter is tipped with five circular splines that can change shapes — including a flower — to fit into the entry of veins, circle and isolate them.
The Farapulse uses electrical pulses to create pores in the cell membranes and the cells die without heat or freezing, Sbaity said. It's safe for the structure of the veins and structures around them.
Boston Scientific reported that 12-month data from a pivotal clinical trial to directly compare the efficacy and safety of the Farapulse system against standard-of-care ablation found that Farapulse therapy was as safe and effective as conventional thermal ablation, with statistically shorter ablation times and a quicker learning curve for physicians.
"That made the procedure itself more effective and more safe, " he said. Sbaity and his partner, Dr. Matt Gaskill, performed the first Farapulse procedure in the state. "In reviewing the literature for a while, we were seeing that this is the future of ablation."
It's faster, more effective and safer, he said. Both are done via a catheter through the groin and into the same chamber of the heart. So it allows the flexibility to add another procedure without increasing time and risks.
The dual procedure has to be guided by internal imaging, and Sbaity took a further advanced step by employing intracardiac ultrasound — also called intracardiac echocardiography, ICE — instead of the usual transesophageal echocardiography, TEE.
TEE requires a second physician sending a scope down the throat, posing the risk of esophageal damage, the American Heart Association says. ICE can be performed by the primary physician doing the catheter procedure, avoiding the additional intubation and damage risks.
Only 8 % of cases of appendage closure in country are done with ICE, Sbaity said.
Combining the two procedures, Sbaity said, allows him to offer the patient advanced treatment of both problems, with the risks associated with separate procedures pared down to one, and with reduced recovery time.
I think this is the wave of the future, combining the two procedures together whenever both are necessary, " he said.
The Mon team is participating in clinical trials comparing appendage closure against blood thinners for people who are not having problems with blood thinners, he said. One study showed closure is better statistically and better in terms of risks. "I think the other two studies will probably prove the same."
What that means, he said, "if it goes that way, then anyone on blood thinner who goes for an ablation would as well want to close the appendage." This would increase the number of patients who benefit from the combined procedure. He expects most patients will want it.
Sbaity said he has done just the one combined procedure so far, but five more are scheduled.
"We're proud here at Mon to offer the most advanced technologies for our patients in West Virginia, " he said, "and we always want to be and have been at the forefront of innovation. That allows the population of West Virginia to have access to the most excellent, best care in the country."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Boston Scientific (NYSE:BSX) Secures US$30-45 Million Deal with Bittium for ECG Devices
Boston Scientific recently entered into a significant agreement with Bittium Biosignals Ltd. to supply ECG devices, valued between USD 30 to 45 million, which strengthens their cardiac diagnostics offerings. Despite this positive development, Boston Scientific's share price saw a modest decline of 1.54% over the last quarter. This movement is in line with broader market conditions, which have remained flat in recent days and risen over the past year. Positive earnings results and future growth projections would have added weight to broader market moves, maintaining the company's alignment with general market trends. Be aware that Boston Scientific is showing 1 warning sign in our investment analysis. AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The recent agreement between Boston Scientific and Bittium Biosignals Ltd. holds significant potential for bolstering the company's cardiac diagnostics segment. The deal, valued at US$30 to 45 million, could lead to improved revenue and earnings forecasts, given the expected expansion in product offerings. This development might offset some negative factors, such as tariffs and regulatory pressures impacting earnings, by providing a pathway for revenue growth in key markets. Over the past five years, Boston Scientific's shares have delivered a total return, including dividends, of 169.47%. This performance illustrates the company's longer-term growth despite short-term volatility, such as the recent 1.54% share price decline over the last quarter. In comparison, over the past year, Boston Scientific has exceeded both the US Market and US Medical Equipment industry performances, returning more than 12.6% and 9% respectively. The positive uptick in cardiac diagnostics may influence future revenue and earnings forecasts, potentially improving the company's profit margin, which analysts expect to grow from 11.6% to 16.9% over three years. Meanwhile, the share price's current discount to the consensus analyst price target suggests room for growth, as the target is US$117.02, approximately 10.3% above the present share price of US$104.12. Investors should weigh these aspects against market dynamics and the company's ability to capitalize on its new innovations and acquisitions. Click to explore a detailed breakdown of our findings in Boston Scientific's financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:BSX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
Emerging markets remain a vital growth engine for Boston Scientific Corporation BSX, anchoring the company's broader international strategy and long-term expansion plans. In the first quarter of 2025, BSX's emerging market operations, which include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand, and Canada, delivered robust operational sales growth of approximately 9.8% year over year. This performance, fueled by favorable economic trends, expanding healthcare infrastructure, and sustained investment, was delivered despite ongoing geopolitical headwinds. Boston Scientific continues to view these high-potential regions as central to driving adoption of its diverse, minimally invasive medical technologies. Emerging markets offer strong growth opportunities for the medical device industry, fueled by trends such as preventive healthcare, portable diagnostics and digital health adoption. Per India Brand Equity Foundation, India's medical device market was valued at $15.35 billion in 2023 and is expected to reach $20.51 billion by 2029 (CAGR 5.35%). China is a key market, supported by its large population, growing middle class and simplified regulatory pathways. Brazil is another major market with a large population and expanding economy, attracting medical device manufacturers. Southeast Asian countries like Thailand, Vietnam and the Philippines are also rising in importance due to rapid economic growth. Boston Scientific's strong performance in emerging markets underscores the strategic importance of these regions in driving the company's long-term international growth. As healthcare needs continue to evolve across these rapidly growing economies, we expect Boston Scientific's sustained investment, localized strategies, and diversified portfolio position to help capture future growth and maintain its leadership in the global medical device space. Competition in emerging markets remains intense, with key players like Abbott Laboratories ABT and Medtronic MDT actively expanding their global reach. Abbott, which derives over 60% of its total revenues from outside the United States, has shown consistent strength in emerging economies. In the first quarter of 2025, its Established Pharmaceuticals Division ('EPD'), focused almost entirely on emerging markets, posted high single-digit organic growth, driven by strong demand in several countries across Asia, Latin America and the Middle East. Abbott continues to localize its branded generics product portfolio to address regional healthcare needs. Similarly, Medtronic generated nearly 49% of its revenues from international markets in the fourth quarter of fiscal 2025, underscoring its global reach. The company's emerging market business grew in the mid-single digits during the quarter, with notable strength in India, Southeast Asia and Eastern Europe. Medtronic's strategy in these regions centers on expanding access to advanced medical technologies and addressing unmet clinical needs through localized engagement and tailored product offerings. Shares of Boston Scientific have gained 35.8% in the past year compared with the industry's growth of 9.6%. The S&P 500 composite also grew 12.2% in the same period. Image Source: Zacks Investment Research From a valuation standpoint, BSX trades at a forward price-to-earnings ratio of 33.69, above the industry's 21.73. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BSX's earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Yahoo
Boston Scientific ends TAVR sales; J&J shares Monarch robot data
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Boston Scientific said Wednesday it plans to end worldwide sales of its transcatheter aortic valve replacement systems, citing regulatory hurdles. The company will discontinue its Acurate Neo2 and Acurate Prime TAVR systems, which are sold in Europe, and will not pursue Food and Drug Administration approval for the devices. Boston Scientific said in a regulatory filing that the decision followed recent discussions with regulators, adding that the products faced increased requirements to maintain approvals in global markets and to obtain approvals in new regions. The company had told investors the 'path to approval in the U.S. was unclear and the approval requirements in Europe would be even greater,' Needham analyst Mike Matson wrote in a research note Wednesday. The decision followed Boston Scientific missing its primary endpoint in a trial comparing its Acurate Neo2 device to other TAVR systems. The Acurate business brought in about $200 million in sales last year, Matson wrote. 'Given the product's mixed clinical track record and complicated path to US approval, we're not surprised by Boston's choice to discontinue the product and redirect its time, effort, and dollars elsewhere,' J.P. Morgan analyst Robbie Marcus wrote in a research note. Marcus views the decision as the right strategy for Boston Scientific, even if the company takes a hit in the short term. Johnson & Johnson shared results of a study that found the company's Monarch bronchoscopy robot was able to reach small, peripheral lung nodules in more than 98% of cases. The robotic platform was able to locate and biopsy the nodules with a safety rate comparable to non-robotic bronchoscopy techniques, the company said in a Wednesday announcement. The TARGET study was published in Chest Journal on April 26 and was sponsored by J&J subsidiary Auris Health. The single-arm trial enrolled 679 people in the U.S., Canada and Hong Kong. Auris first received FDA clearance for the Monarch robot in 2018. J&J acquired the company a year later for $3.4 billion in cash. A software update for the system, intended to improve accuracy in reaching suspicious nodules, was cleared in March. Medtronic said Tuesday that a technology it is developing for its pulse oximeters was accepted into the FDA's Safer Technologies Program. The program is intended to support expedited development, assessment and review of devices that are expected to improve the safety of currently available devices. Medtronic is developing a technology to integrate patient- and sensor-specific data into oxygen saturation calculations used by its Nellcor pulse oximeters. Pulse oximeters have faced recent scrutiny by the FDA after studies have shown the devices may be less accurate for people with darker skin pigmentation. The agency issued a draft guidance in January updating testing recommendations for the devices, but it has not yet finalized the guidance. Last year, Medtronic agreed to provide labels and brochures to California hospital customers about the potential for flawed readings as part of a settlement with Roots Community Health, which sued 13 companies that make or sell pulse oximeters over the risk of disparities in treatment. Recommended Reading Edwards gains expanded TAVR label for asymptomatic patients Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data